This suggests that inhibition of Smad3-dependent molecules specifically associated with cardiac fibrosis, rather than targeting the entire TGF-β/Smad3 signaling, may be a better approach to treat hypertensive cardiovascular disease. The gene discussed is TGFB1; the disease is hypertensive heart disease.